newsfilter
← Latest News
GlobeNewswire·

CapsoVision Reports First Quarter 2026 Financial Results

CV
  • CapsoVision reported Q1 2026 revenue of $2.8 million, stable compared to Q1 2025.
  • Gross profit decreased 11% to $1.3 million with margins falling to 48% due to U.S. trade policies & tariffs.
  • Operating expenses rose 22% to $8.4 million, driven by CMOS sensor development with Canon Inc. & clinical trials for the second-generation CapsoCam Colon.
  • The company secured key renewals with Indiana University Health Systems, Providence Health Systems, & Gastro Health.
  • CapsoCam Plus® has been used by over 167,000 patients as of March 31, 2026.
  • AI-assisted reading for CapsoCam Plus® is on track for mid-year FDA clearance with a commercial launch expected shortly after.
  • The second-generation CapsoCam Colon 510(k) submission is scheduled for Q3 2026.
  • A clinical study for CapsoCam UGI in pancreatic cancer detection began with the first patient enrolled in May 2026.
  • CapsoVision closed a $14 million private placement of public equity on March 16, 2026.
  • Cash & cash equivalents totaled $17.9 million as of March 31, 2026.
  • The company reported a net loss of $7.033 million for Q1 2026, compared to $5.375 million in Q1 2025.
  • Net loss per share was $0.15 for Q1 2026, compared to $2.49 in Q1 2025.
  • A conference call to discuss results was held on May 14, 2026, at 4:30 p.m. ET.